An 'Omics' Perspective on Cardiomyopathies and Heart Failure

Area of Science:

• Cardiology
• Molecular Biology
• Bioinformatics

Background:

• Pathological heart enlargement, such as hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), stems from diverse genetic and non-genetic triggers.
• The clinical progression of cardiac hypertrophy varies widely, from asymptomatic states to severe heart failure and sudden cardiac death (SCD).

Purpose of the Study:

• To explore the molecular underpinnings of cardiac hypertrophy using unbiased omics approaches.
• To investigate the role of post-transcriptional gene regulation in normal and diseased hearts.

Main Methods:

• Utilized unbiased omics studies to analyze molecular alterations in cardiac hypertrophy.
• Examined changes in mechanotransduction, mitochondrial function, oxidative stress, and extracellular matrix composition.
• Analyzed gene expression patterns, focusing on post-transcriptional regulation.

Main Results:

• Omics analyses reveal key molecular pathways involved in cardiac hypertrophy, including altered mechanotransduction and mitochondrial energetics.
• Post-transcriptional gene regulation emerges as a critical factor in both physiological and pathological cardiac remodeling.
• Identified significant molecular changes related to oxidative stress and extracellular matrix remodeling.

Conclusions:

• Cardiac hypertrophy is a complex process influenced by multiple molecular factors.
• Post-transcriptional regulation plays a dominant role in the molecular landscape of the heart.
• There is a critical need for improved bioinformatics tools to integrate omics data with clinical information for a comprehensive understanding of heart disease.